AstraZeneca Plc (AZN)

39.21
NYSE : Health Technology
Prev Close 38.95
Day Low/High 39.09 / 39.51
52 Wk Low/High 31.99 / 40.16
Avg Volume 4.01M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 97.35B
EPS 1.20
P/E Ratio 17.47
Div & Yield 1.37 (3.49%)
Charter Says No to Sprint - 5 Things You Must Know Before the Market Opens

Charter Says No to Sprint - 5 Things You Must Know Before the Market Opens

U.S. stock futures rise Monday following a record closing high for the Dow Jones Industrial Average to end last week.

IMFINZI™ (durvalumab) Granted Breakthrough Therapy Designation By US FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer

IMFINZI™ (durvalumab) Granted Breakthrough Therapy Designation By US FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for IMFINZI™ (durvalumab), an...

AstraZeneca Gets Breakthrough Designation For Imfinzi Following Pacific Trial

AstraZeneca Gets Breakthrough Designation For Imfinzi Following Pacific Trial

AstraZeneca's Imfinzi gets reprieve after MYSTIC failure

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too

The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

The British pharma company suffers a setback with a lung-cancer drug it touted as a defense against a Pfizer takeover bid three years ago, and could be back in play.

AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers

AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers

Shares lost more than 16% in London trading

Nasdaq Tumbles as Tech Takes a Turn Lower

Nasdaq Tumbles as Tech Takes a Turn Lower

The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.

Amazon, AstraZeneca Are Explosive Stocks -- AZN, VZ, TWTR, CMCSA, AMZN, LUV

Amazon, AstraZeneca Are Explosive Stocks -- AZN, VZ, TWTR, CMCSA, AMZN, LUV

But not all stocks were helping to push the market higher.

European Benchmarks Sink Despite Solid Corporate Earnings

European Benchmarks Sink Despite Solid Corporate Earnings

Losses at several major index constituents sank markets Thursday.

AstraZeneca Shares Sink on Lackluster Mystic Drug Results

AstraZeneca Shares Sink on Lackluster Mystic Drug Results

AstraZeneca shares are tanking.

Wall Street Trades at Records as Facebook Rallies

Wall Street Trades at Records as Facebook Rallies

Stocks are higher.

Facebook, Twitter, Procter & Gamble, AstraZeneca: Hot Stocks to Watch

Facebook, Twitter, Procter & Gamble, AstraZeneca: Hot Stocks to Watch

These stocks were moving big before the market opened.

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.

Stock Futures Power Higher on Earnings Beat From Facebook

Stock Futures Power Higher on Earnings Beat From Facebook

Stock futures are higher.

Facebook and PayPal Just Made Everyone Do a Double Take -- Watch 'Five Before the Bell'

Facebook and PayPal Just Made Everyone Do a Double Take -- Watch 'Five Before the Bell'

Facebook blows everyone away, again.

TAGRISSO® (osimertinib) Significantly Improves Progression-Free Survival In The Phase III FLAURA Trial For Lung Cancer

TAGRISSO® (osimertinib) Significantly Improves Progression-Free Survival In The Phase III FLAURA Trial For Lung Cancer

AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with TAGRISSO ® (osimertinib) compared to current...

AstraZeneca's Lung Cancer Treatment Fails Trial; Q2 Earnings Top Estimates

AstraZeneca's Lung Cancer Treatment Fails Trial; Q2 Earnings Top Estimates

AstraZeneca calls MYSTIC results "disappointing".

European Stocks Set to Drift Lower Ahead of Active Week For Corporate Earnings

European Stocks Set to Drift Lower Ahead of Active Week For Corporate Earnings

Global equity rally takes a breather.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

We're Downgrading Snap-On

Despite earnings beat, company is in a 'battleground.'

China Was Right to Walk Away From Failed U.S. Trade Talks

China Was Right to Walk Away From Failed U.S. Trade Talks

The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.

AstraZeneca Shares Top FTSE 100 After Drugmaker Says CEO Will Host Late-July Earnings Call

AstraZeneca Shares Top FTSE 100 After Drugmaker Says CEO Will Host Late-July Earnings Call

AstraZeneca shares rose after the group said its CEO would host an earnings call later this month following speculation he was to take up a similar role Teva Pharmaceuticals.

AstraZeneca Stock Surges After Company Confirms Soriot Staying on as CEO

AstraZeneca Stock Surges After Company Confirms Soriot Staying on as CEO

Rumors swirled that Pascal Soriot would leave for rival Teva Pharmaceuticals.

Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter

Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter

CEO Pascal Soriot may be on his way to Israel's Teva Pharmaceuticals ahead of key drug trial information release.

Will AstraZeneca's CEO Leave for Teva? Credit Suisse Doesn't Think So

Will AstraZeneca's CEO Leave for Teva? Credit Suisse Doesn't Think So

Neither company has confirmed Pascal Soriot's move.

European Stocks Hold Gains Thursday as Optimism Hunkers Down

European Stocks Hold Gains Thursday as Optimism Hunkers Down

European benchmarks held gains much of Thursday.

AstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot

AstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot

AstraZeneca shares dropped in the first hours of trading Thursday after it was reported that Teva Pharmaceuticals was courting its CEO.

Teva Stock Jumps as New CEO Expected to Be Named

Teva Stock Jumps as New CEO Expected to Be Named

AstraZeneca CEO Pascal Sorio will reportedly take over at Teva.

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.

TheStreet Quant Rating: B (Buy)